

Programme Schedule

Sunday September 7, 2014

Opening Ceremony

Portugal: the Right Place to build Partnerships in Health

Dr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)

Partnership between Public and Private Sources: Pharma and IMI Perspective

Dr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)

EFMC Award Ceremony

The Nauta Award for Pharmacochemistry Pursuing Compound Quality

Dr Paul LEESON
(GLAXOSMITHKLINE, Nuneaton, United Kingdom)

High Resolution Mass Spectrometry in Clinical Proteomics

Prof. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)

Welcome Reception

Programme Schedule

Monday September 8, 2014

The UCB-Ehrlich Award for Excellence in Medicinal Chemistry Small Molecule Control Of Intracellular Protein Levels

Prof. Craig CREWS
(YALE UNIVERSITY, New Haven, CT, United States)

The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery Thermodynamics Assisted Drug Discovery

Dr György G. FERENCZY (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
Prof. György KESERU (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

Exhibition & Coffee

Session 1.1 Inflammation: the Common Link in Multifactorial Disorders?

10:30 Session Chair

Prof. Angeliki KOUROUNAKIS
(UNIVERSITY OF ATHENS, Athens, Greece)

10:35 Inflammation, Obesity and Metabolic Disease

Dr Ajay CHAWLA
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

11:15 CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis

Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

11:35 The Discovery of APD334, a Selective S1P1 Functional Antagonist

Dr Robert JONES
(ARENA PHARM, SAN DIEGO, United States)

11:55 Discovery of Small Molecule Ror? Modulators for the Treatment of Autoimmune Diseases

Dr Frank NARJES
(ASTRAZENECA, Gothenburg, Sweden)

Session 1.2 Computational Approaches To Guide Medicinal Chemistry

10:30 Session Chair

Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

10:35 Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function

Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

11:15 Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter

Dr Chris CHIPOT
(UNIVERSITY OF ILLINOIS, Urbana, United States)

11:35 Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?

Dr Clara CHRIST
(BAYER, Berlin, Germany)

11:55 P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies

Mr Ricardo FERREIRA
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

Session 1.3 Organic Synthesis that Changed Medicinal Chemistry

10:30 Session Chair

Dr Morten JORGENSEN
(H. LUNDBECK A/S, Valby, Denmark)

10:35 Recent Advances In Asymmetric Catalysis

Programme Schedule

Prof. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

11:15 New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids

Prof. Pier Giorgio COZZI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

11:35 Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry

Dr Marc MOSRIN
(BAYER CROPSOURCE AG, Frankfurt am Main, Germany)

11:55 Development of Novel Building Blocks to Accelerate Drug Discovery

Dr Pavel MYKHAILIUK
(ENAMINE, Kyiv, Ukraine)

Exhibition & Lunch

Session 2.4 Combating Antibiotic Resistance

13:15 Session Chair

Prof. Ada YONATH
(WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel)

13:20 Aminoglycoside Mechanisms of Action, Resistance and Toxicity – Prospects for Antibiotic Drug Development

Prof. Erik BOETTGER
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

14:00 Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target

Prof. Stephen DOUTHWAITE
(UNIVERSITY OF SOUTHERN DENMARK, Odense, Denmark)

14:20 The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design

Dr Moran SHALEV-BENAMI
(WEIZMANN INSTITUTE, Rehovot, Israel)

14:40 Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents

Dr Martin EMPTING
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

Session 2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis

13:15 Session Chair

Prof. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)

13:20 Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development

Dr Esther SCHMITT
(NOVARTIS, Basel, Switzerland)

14:00 Sponging Off Nature for New Drug Leads

Prof. Raymond ANDERSEN
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

14:20 Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya

Prof. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)

14:40 From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein

Dr Fanny ROUSSE
(ICSN - CNRS, Gif sur Yvette, France)

Session 2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury (Eufeps Session)

13:15 Session Chair

Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)

13:20 Mechanism-Based Prediction of Drug-Induced Liver Injury

Programme Schedule

Dr Christopher GOLDRING
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)

14:00 Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites

Prof. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)

14:20 Being More Certain About Uncertainty In Computational Toxicology Modeling

Dr Scott BOYER
(KAROLINSKA INSTITUTET, Barcelona, Spain)

14:40 Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?

Dr Alexandra ANTUNES
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)

Exhibition & Coffee

MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application

Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Session 3.7 EFMC Session

15:55 Session Chair

Dr Phil JONES
(UNIVERSITY OF DUNDEE, Glasgow, United Kingdom)

16:00 The Open Phacts Discovery Platform - Semantic Data Integration For Medicinal Chemists

Prof. Gerhard ECKER
(UNIVERSITY OF VIENNA, Vienna, Austria)

16:30 European Lead Factory - Game Changing For Innovative Medicines

Dr Dimitrios TZALIS
(TAROS CHEMICALS, Dortmund, Germany)

17:00 Funding Opportunities with the Innovative Medicines Initiative 2

Dr Colm CARROLL
(INNOVATIVE MEDICINES INITIATIVE, Brussels, Belgium)

Poster Session I and Networking

End of the day

Concert (free of charge, but subject to registration)

Programme Schedule

Tuesday September 9, 2014

Prize Ceremony

EFMC Prize for a Young Medicinal Chemist in Industry Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC

Dr Grazia PIZZI
(NOVARTIS PHARMA, Basel, Switzerland)

EFMC Prize for a Young Medicinal Chemist in Academia Inhibitors and Substrates of the Human Lysine Deacetylase Enzymes

Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Plenary Lecture

Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

Exhibition & Coffee

Session 4.8 Applications of Positron Emission Tomography in Drug Discovery (ACS Session I)

10:30 Session Chair

Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

10:35 PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery

Dr Peter J.H. SCOTT
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

11:15 A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development

Dr Chad ELMORE
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)

11:35 Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging

Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

11:55 Quantitative Imaging of Mglu5 Allosteric Binding Site and its Occupancy by Positron Emission Tomography with The Novel Fluorine-18 Labelled Probe [18f]Pss232

Dr Stefanie KRAMER
(ETH ZÜRICH, Zürich, Switzerland)

Session 4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers

10:30 Session Chair

Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Los Angeles, United States)

10:35 BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction

Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Los Angeles, United States)

11:15 A First In Class Chemical Probe For Family VIII Bromodomains

Dr Dafydd OWEN
(PFIZER, Cambridge, United States)

11:35 Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins

Prof. Paul FISH
(UCL SCHOOL OF PHARMACY, London, United Kingdom)

Programme Schedule

11:55 Interrogation the Bromodomain Family through Chemical Biology

Dr Steve BELLON
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Session 4.10 Organic Synthesis: New Developments (EuChemS Session)

10:30 Session Chair

Prof. Péter MÁTYUS (SEMMELWEIS UNIVERSITY, Budapest, Hungary)
(THERMO FISHER SCIENTIFIC)

10:35 Experiences with Natural Product Total Synthesis

Prof. Alois FÜRSTNER
(MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

11:15 New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds

Prof. Artur M.S. SILVA
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)

11:35 Fast and Safe Synthesis of Pharmaceutically Relevant Molecules

Prof. Thomas WIRTH
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)

11:55 Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases

Prof. Marko D. MIHOVILOVIC
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)

Exhibition & Lunch

Session 5.11 Oncology: Kinases and Beyond

13:15 Session Chair

Dr Mario VARASI
(EUROPEAN INSTITUTE OF ONCOLOGY, Milano, Italy)

13:20 Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer

Prof. Filippo MINUTOLO
(UNIVERSITY OF PISA, Pisa, Italy)

14:00 Novel Anti-Cancer Treatment Targeting Vps34

Dr Jessica MARTINSSON
(SPRINT BIOSCIENCE, Stockholm, Sweden)

14:20 Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors

Dr Maria Emilia DI FRANCESCO
(UTMD ANDERSON CANCER CENTER, Houston, United States)

14:40 Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a

Dr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)

Session 5.12 Recent Advances in Anti-infective Agents (AFMC Session)

13:15 Session Chair

Dr Ming-Hua HSU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

13:20 Development of New Anti-Infective Agents and a Novel Delivery Strategy

Prof. Reuben JIH-RU HWU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

14:00 Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds

Prof. Han-Young KANG
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)

14:20 Novel Boron-containing Anti-infective Agents

Programme Schedule

Dr Jacob PLATTNER
(ANACOR PHARMACEUTICALS, Palo Alto, United States)

14:40 Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists

Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

Session 5.13 New Strategies for Lead Generation

13:15 Session Chair

(THERMO FISHER SCIENTIFIC)

13:20 Integration of New Chemical Diversity and Design Approaches in Lead Generation

Dr Timothy GRESE
(ELI LILLY AND COMPANY, Indianapolis, United States)

14:00 The Impact of Polypharmacology on Lead Generation

Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Girona, Spain)

14:20 Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation

Dr Steve WOODHEAD
(TAKEDA CALIFORNIA, San Diego, United States)

14:40 Discovery of the First and Only Small Molecule IL-17 Blockers

Dr Nils HANSEN
(VIPERGEN, Copenhagen, Denmark)

Exhibition & Coffee

Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery

Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Poster Session II and Networking

End of the day

Programme Schedule

Wednesday September 10, 2014

IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D
Dr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)

Innovation Through Chemistry at the Interfaces of the Scientific Disciplines
Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)

Exhibition & Coffee

Session 6.14 New Chemical Entities: Beyond Small Molecules

- 10:30 Session Chair**
Prof. Stan VAN BOECKEL
(LEIDEN INSTITUTE OF CHEMISTRY, Leiden, The Netherlands)
- 10:35 Cyclic Peptides from the nature to the synthetic ones**
Prof. Fernando ALBERICIO
(INSTITUTE FOR RESEARCH IN BIOMEDICINE, Durban , South Africa)
- 11:15 Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics**
Dr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)
- 11:35 Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells**
Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)
- 11:55 Novel Inhibitors of Alzheimer's Associated Beta-Secretase-Clusters of Heparan Sulfate**
Dr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)

Session 6.15 Novel Agents for the Treatment of C. Difficile (ACS Session II)

- 10:30 Session Chair**
Prof. Steven FIRESTINE
(WAYNE STATE UNIVERSITY, Detroit, United States)
- 10:35 Discovery and Development of Surotomycin for the Treatment of C. difficile**
Dr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)
- 11:15 Invited Lecture**
Dr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)
- 11:35 Targeting Spore Germination to Prevent Clostridium Difficile Infections**
Dr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)
- 11:55 Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)**
Dr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

Session 6.16 Kinetic and Thermodynamic Aspects of Ligand Binding

- 10:30 Session Chair**
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
- 10:35 Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors**

Programme Schedule

Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

- 11:15 Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.**

Prof. Iwan DE ESCH
(VU AMSTERDAM, Amsterdam, The Netherlands)

- 11:35 Medicinal Chemistry Optimisation Of Binding Kinetics**

Prof. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

- 11:55 CRTH2: Can Residence Time Help?**

Dr Elena GOMEZ
(ALMIRALL, BARCELONA, Spain)

Exhibition & Lunch

Session 7.17 Recent Highlights in Medicinal Chemistry

- 13:15 Session Chair**

Prof. Carlos MONTANARI
(UNIVERSITY OF SAO PAULO, Sao Paulo, Brazil)

- 13:20 Cebranopadol, a Novel, Potent Analgesic**

Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)

- 13:40 Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies**

Dr Wolfgang SCHWEDE
(BAYER, Berlin, Germany)

- 14:00 Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease**

Dr Christopher LUCKHURST
(BIOFOCUS, Saffron Walden, United Kingdom)

- 14:20 Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors**

Dr Erin DIMAURO
(AMGEN, Cambridge, United States)

- 14:40 Novel Potent Inhibitors of the Histone Demethylase KDM1A**

Dr Paola VIANELLO
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)

Session 7.18 Hot Topics in Ion Channels

- 13:15 Session Chair**

Prof. Brian COX
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Brighton, United Kingdom)

- 13:20 An Introduction To Ion Channels As Drug Targets**

Prof. Morten GRUNNET
(LUNDBECK, Valby, Denmark)

- 14:00 CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study**

Dr Gerard GIBLIN
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)

- 14:20 Pain-relieving Peptides Targeting Acid-Sensing Ion Channels**

Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

- 14:40 Discovery of Ivacaftor (Vx-770), a Cftr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients**

Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

Session 7.19 Allosteric Modulators for CNS Diseases

Programme Schedule

13:15 Session Chair

Dr Wolfgang FROESTL
(AC IMMUNE, Lausanne, Switzerland)

13:20 Functional and Structural Insights into GPCR Allostery

Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Parkville, Australia)

14:00 Discovery of the mGlu5 Negative Allosteric Modulator RO4917523

Dr Georg JAESCHKE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

14:20 Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies

Prof. Ana MARTINEZ
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

14:40 Antibodies as Tools to Enable Small Molecule Drug Discovery

Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)

Excursions

Banquet

Programme Schedule

Thursday September 11, 2014

Session 8.20 GPCR Structural Biology: New Therapeutic Opportunities?

08:30 Session Chair

Prof. Jan STEYAERT
(VUB, Brussels, Belgium)

08:35 High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies

Dr. Jonathan MASON
(HEPTARES THERAPEUTICS, Cambridge, United Kingdom)

09:15 Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs

Prof. Jan STEYAERT
(VUB, Brussels, Belgium)

09:35 Covalent Agonists Facilitating Crystallisation of GPCRs

Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

09:55 Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening

Dr David RODRIGUEZ DIAZ
(STOCKHOLM UNIVERSITY, Solna, Sweden)

Session 8.21 Neglected Tropical Diseases: Shaping Future Trends

08:30 Session Chair

Prof. Kelly CHIBALE
(UNIVERSITY OF CAPE TOWN, Cape Town, South Africa)

08:35 Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites

Prof. Reto BRUN
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

09:15 Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery

Prof. Adam RENSLO
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

09:35 Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box

Dr Francisco-Javier GAMO
(GLAXOSMITHKLINE, Madrid, Spain)

09:55 Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei

Prof. Jennifer WOODRING
(NORTHEASTERN UNIVERSITY, Boston, United States)

Session 8.22 New Therapies for Metabolic Disorders

08:30 Session Chair

Dr Jürgen MACK
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

08:35 Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing

Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)

09:15 1,1'-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors

Dr Thomas TRIESELNANN
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

09:35 Omarigliptin: A Once-weekly Oral Antidiabetic Agent

Dr Tesfaye BIFTU
(MERCK, Rahway, United States)

09:55 Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism

Dr Anneli NORDQVIST
(ASTRAZENECA, BIOPHARMACEUTICALS R&D, Gothenburg, Sweden)

Programme Schedule

Exhibition & Coffee & Snacks

Session 9.23 Late Breaking News

- 10:45 Session Chair**
Dr Laurence LAFANECHERE
(CNRS, Grenoble, France)
- 10:50 CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization**
Dr Maurizio DELCANALE
(CHIESI, Parma, Italy)
- 11:10 The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma**
Dr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)
- 11:30 Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases**
Dr Franz VON NUSSBAUM
(BAYER PHARMA, Berlin, Germany)
- 11:50 Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD**
Dr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)
- 12:10 Identifying Selective Inhibitors of FGFR4 Kinase**
Dr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

Session 9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options

- 10:45 Session Chair**
Dr Andrew THOMAS
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- 10:50 CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson's Disease**
Prof. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)
- 11:30 Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect**
Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- 11:50 Fragment-Based Discovery of BACE Inhibitors for Alzheimer's Disease**
Dr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)
- 12:10 The Evolution of an in vivo Efficacious Bace1 Inhibitor**
Dr Daniel OEHLRICH
(JANSSEN RESEARCH AND DEVELOPMENT, Beerse, Belgium)

Session 9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling

- 10:45 Session Chair**
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 10:50 Translational Modeling in Support to Discovery and Early Development**
Dr Thierry LAVE
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- 11:30 Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721**
Dr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)
- 11:50 A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement**

Programme Schedule

Mr Alban BUJARD
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

12:10 Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer

Dr Martyna KRZYKAWSKA-SERDA
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

**Closing Lecture
Personalised Medicinal Systems Chemistry**

Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Closing Remarks, Poster Prizes and Welcome to EFMC-ISMIC 2016